X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-discontinue-levemir-insulin-us-market-2023-11-08/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208583
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203313
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203314
https://www.globenewswire.com/news-release/2022/04/28/2431662/0/en/Once-weekly-insulin-icodec-demonstrates-superior-reduction-in-HbA1c-vs-insulin-degludec-in-people-with-type-2-diabetes-in-ONWARDS-2-phase-3a-trial.html
https://www.pharmacompass.com/pdf/news/novo-nordisk-issues-voluntary-nationwide-recall-of-levemir-1620795213.pdf
http://www.pharmatimes.com/news/tresiba_lowers_risk_of_hypos_in_type_ii_diabetes_1302119
https://www.fiercepharma.com/pharma/easd-novo-nordisk-s-tresiba-misses-main-mark-head-to-head-tilt-sanofi-s-toujeo
https://www.biopharmadive.com/news/novo-faces-shareholder-suit-over-insulin-sales-disclosures/561091/
https://www.fiercepharma.com/marketing/sanofi-s-toujeo-tops-novo-nordisk-s-tresiba-tough-to-treat-diabetes-subgroup
https://www.fiercepharma.com/marketing/sanofi-launches-diabetes-campaign-to-advance-personalized-patient-approach
http://www.pharmatimes.com/news/study_shows_reduced_hypoglycaemia_after_switch_to_tresiba_1280905
https://www.fiercepharma.com/pharma/diabetes-meds-coverage-improves-but-novo-s-oral-semaglutide-could-disrupt-them-all-analyst
http://www.pmlive.com/pharma_news/novo_nordisk_preps_for_speedy_oral_glp-1_drug_filing_1277020
http://www.pharmatimes.com/news/novo_nordisk_sees_revenues_drop_in_q2_1248067
http://www.pmlive.com/pharma_news/novo_nordisks_ozempic_is_quick_out_of_the_blocks,_chasing_lillys_trulicity_1248087
https://www.reuters.com/article/us-novo-nordisk-results/drug-maker-novo-nordisk-expects-lower-us-prices-next-year-idUSKBN1KT0GZ
https://www.fiercepharma.com/pharma/revlimid-and-pomalyst-price-increases-could-celgene-be-next-trump-s-to-call-list
https://www.biospectrumasia.com/news/25/11228/sanofi-presents-positive-results-of-long-acting-insulin-toujeo.html
https://www.fiercepharma.com/marketing/novo-nordisk-s-tresiba-snags-label-boost-highlights-hypo-safety
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sanofi-bets-on-india-with-portfolio-of-drugs-for-diabetes-rare-diseases/articleshow/62895424.cms
https://www.prnewswire.com/news-releases/insulia-receives-fda-clearance-and-ce-mark-to-integrate-basaglar-and-tresiba-300557527.html
http://www.pharmatimes.com/news/chmp_endorses_tresiba_label_update_in_the_eu_1206660
http://www.pharmatimes.com/news/cardiovascular_outcomes_dominate_easd_1205374
http://www.foxbusiness.com/features/2017/08/15/when-new-and-improved-fails-insulin-maker-2.html
http://www.fiercepharma.com/pharma/novo-nordisk-files-to-add-lantus-matching-cv-data-to-tresiba-s-european-label
http://www.prnewswire.com/news-releases/tresiba-demonstrated-no-increased-risk-of-major-cardiovascular-events-and-significant-reduction-in-rates-of-severe-hypoglycaemia-compared-to-insulin-glargine-u100-in-the-devote-trial-300472358.html
http://www.fiercepharma.com/pharma/novo-s-tresiba-matches-sanofi-rival-lantus-cv-safety-study-and-cuts-down-rate-severe
https://globenewswire.com/news-release/2017/05/30/999857/0/en/Robert-A-Ingram-Named-Chairman-of-BioCryst-Pharmaceuticals-Inc.html
http://www.fiercepharma.com/pharma/novo-ceo-cites-volatile-environment-u-s-politics-cut-to-2017-growth-prospects
http://www.fiercepharma.com/marketing/sanofi-beats-novo-to-launch-diabetes-combo-soliqua-kicking-off-market-share-grab
http://www.fiercepharma.com/pharma/sanofi-sues-novo-over-misleading-tresiba-marketing-materials
http://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-of-tresiba-insulin-degludec-injection-100-uml-200-uml-for-use-in-children-and-adolescents-with-diabetes-300381285.html
http://www.reuters.com/article/us-novo-nordisk-insulin-idUSKBN13O2I5
http://www.nasdaq.com/article/oramed-vs-novo-nordisk-in-race-for-oral-glp-1-cm715418
https://www.japantoday.com/category/health/view/novo-sanofi-go-head-to-head-as-fda-clears-new-diabetes-drugs
https://globenewswire.com/news-release/2016/11/21/891877/0/da/Novo-Nordisk-f%C3%A5r-FDA-godkendelse-for-Xultophy-100-3-6-i-USA.html
http://www.pharmatimes.com/news/novo_nordisks_tresiba_backed_for_use_on_nhs_wales_1174815
http://www.fiercepharma.com/pharma/head-start-for-novo-s-combo-med-xultophy-fda-delayed-it-instead
http://www.pmlive.com/pharma_news/novo_nordisks_tresiba_gaining_ground_in_basal_insulin_market_1090898
http://www.fiercepharma.com/marketing/novo-s-tresiba-hits-airwaves-new-tv-campaign
http://www.pharmatimes.com/news/novos_tresiba_beats_sanofis_lantus_on_reducing_hypoglycaemia_1041341
https://globenewswire.com/news-release/2016/05/24/843002/0/en/IDegLira-receives-positive-16-0-vote-in-favour-of-approval-from-FDA-Advisory-Committee.html
http://www.medpagetoday.com/PublicHealthPolicy/FDAGeneral/58091?xid=nl_mpt_DHE_2016-05-24&eun=g655567d0r
Market Place
Share 
